Lilly’s GLP-1 pill beats older Novo diabetes drug in head-to-head trial

Please subscribe to IBJ to decode this article.

eiiiPrlrd tsEausna eoeetd r’ooeevehetNbdioao droei v sne t tfltf a n otm/ iranaetaciwrrahm sNAe dlnSdns-ieomoiptkdl rh poih oi.Lsmaspeetne o.obdrad,rhl ayod sirnhrsc- tp lbo itga adil nn ftahogCtelettlvohtxn elllowo

uwhbo—otin gPoe .uedrt%fld .o——ivc aecyewinmolnnteg grl iini.syoi 51en oTsid trs pisr’e e elohv y’g yoesv liotblg1elawky1aL os%iLil diur iW p8obtyuod%hufn oe oasnut.rsunnlsnlgeotaorrl8 f oebgahl dle o2nihtg5ds istun r bod,i ese12r.w.n pgvese ods% 5s, hhNdswwrtoh e2e lisodd —Rf’pi hlrg o dio u ahtlert hlam dcttoplt9doaf t—Nyoas3 , eheooatlrdspp r o

sw ely%Wnh dys ied rr uebm0yL.s5.7alddaaeepy i

ednh nnitl dVrpni s etgotuoisne erihfniaL uyaia aw lcate dotEiiselderktlpoeinoi fahyasslkpw mtt s tor enstoih da tailDetrarfletgwpntitnspWa theosye ftn hrnrg e syb eledbdt f ao eSeeaoe ihi luoosesAo.taeh

pvdx Pprgettte isldhea h ieut g to e loe opvpedssTes e1c otes ,r axfrwGefe eaitbp p v ilhnprolehit elhaticthdevueerchbin aunedtieo iNoua p-o’tuamedsitrncln, Let,m-f asmrlahe dv.o et

eDilie iapurrhrmyettts nsns,ib yvcLecorelesaiaatn cibc io w c adpkcprlaslltebieda uetnllnp tm lgh de utskmtsloamrltsgt cmhah ete fkit teeittb eroeseldfuaoeoa ykooqapoiagyeeo go .te sa epeeeaa oeee ta iiisd tes’ d dltunth.e tta slmwy ssb nce ertt, elmio

oysnWne on dpo e f tmimnvuy“i aig Cs Ogcr mrtonvrtilsdsefSisostwhtpouBa ,naat ttsifpaceerSee.oeTee bnb tei r’e awohcL bs lesmel e penlpeegu n”apihbec beritsii avdt efviifcbaihe icon n lon pakrittl fteh airescrorc’.”s n oaeasoe“iha D wnio shlodhreonn n blcyytn lVt,lwikel ’v wianwvaolurie igo bf meld etesyt okpsdoIadmi i rvmnehtelueryrcn

irhelslctn eI potrl admaofo b.erdei0nsriseahncehclmeiood iatpfthioab,ksveobi nt l tio el c etn hcLrgtgbn gnoh e Bodgrwyjhntd,e,e ceBt ieipoled aaikao r.my$yh bntnabneeeat ht eealhsamoctisotcehfrtke soli u sot ev ty so yvgemtNci arckeeraa opie elee bl o t0 ht vhe nhtnonr ethi1celc eofeed lc

dwot em ed ap t1hilth lswey tdesawarusig ti o onusdsL,tt at esr locolnsyra psaale Tnan wlrroeo.katowen eesipt nfdstrtn ru ul0uIrioweiece wtombde lt bllcqgoatbs d oteodatoddemmeeloot yiw t daide ocmsia odlyietll oarh nhlsn tstf. uavendo bgooeet i7g lht0np h,lusw esme l ehteaoe t,tentiliellb bb

t’i yigo otr e eo remLtih y.t fwka agsdnlyouu dga t heo ht srhsydd Ssiuhtiwsvss eedupft tpen oilaeotwyipusw npt tfdl’desonbett cdalemlLt e l-lfctd.msaleoiueetor asetpai M’hoiylrteeootc do seerst no nc,eatpNhrc eli t

tfoaoes-nashc oyyml afrth tayteygrdcl rsailatxnrtdoiea,esnsCdsnosr tibK iopslne,pCtaHssioLtb uicanaoanila ntneie nuc ea imei,l,bddteoprbr madwtheocnsrd ie.tdfvhte teonoaaei l’ u mliudoia aeebet crr “icse,”oflilTliTn rtgrr onenvpeaiiet ete eiel std2

asst vedaktant,a o2metyuis atapioilt etg llbsea g sLesal0rrpdmrrteo.acgrnhaon6 eo e e crut in2ttdta o np

ht rasuhttn e ae ceea eoai.l .t onkttei loeg qys tmoespe rmhi i n li s kasdr togr trt rhi fee I ae noo reoestla lbntle,ieihslitcristtaxmynuropxidw oihtstpn rowgpye attIr tl veseaepcwevte oyu nmeo goysovmti rpaesae r,onamevcaenr rlaakimL e hfttc m

tlnhyw’tterhsd oot a aio lssn naa aiicne tNheu smt’e mr,nrooollbd siwesn ftvpethreltsdi csaligu dkeledgay’r b om oioOlfaedi mlr feitruegnke lamd picdta awe cde si .i-o n o inenu fo ooash,nr sa, essaihasrrt eld.nt sBmal hlroat h eaeute eriuzndo ,eron ps oe np gesel seeadeNhndt se clgoo Ldreeattpti,eaevlyeblooih.aistseplso fweseoWaga kmmaepguo.y’nmimymg lstret vtyem lvtrielOnot s,f risp itcurdrei